CSE:ACOG - Post Discussion
Post by
culturedpiggy01 on Feb 23, 2022 3:43pm
$ACOG.v drug shows positive neuroprotection data
$ACOG.v announced histology data from their intranasal ALPHA-1062 Traumatic Brain Injury (TBI) program. The pre-clinical study of ALPHA-1062 treatment was neuroprotective, preserving hippocampal structure, reducing cell loss and promoting neurogenesis compared to no treatment. Learn more here: https://ca.finance.yahoo.com/news/alpha-cognition-announces-positive-neuroprotection-133000722.html
This is excellent news, the drug, if it continues to be as successful in further development could change the course of how we treat TBIs completely. Eagerly awaiting more updates on this.
td, $ACOG.v trading at $0.98 with market cap at $60.27 M
Be the first to comment on this post